INTSNasdaqBiological Products, (No Diagnostic Substances)US GAAP · USD

Intensity Therapeutics, Inc

Intensity Therapeutics, Inc. is a clinical-stage biotechnology company developing intratumoral cancer therapies designed to be injected directly into tumors. Its lead candidate, INT230-6, combines two cytotoxic agents with a proprietary amphiphilic molecule to help the drugs spread within the tumor and enter cancer cells.

Ask about the company
Operating profit (EBIT)-12.0m USD
+27.8 %y/y
Net income-11.6m USD
+28.7 %y/y

Fiscal year 2025 · change from previous year

Development 2022–2025

-20-15-10-50m USD2022: EBIT -7.6 m USD20222023: EBIT -8.3 m USD20232024: EBIT -17 m USD20242025: EBIT -12 m USD2025-12
RevenueOperating profit (EBIT)

Business

Share of revenue
Lead product candidate90 %

INT230-6 is the company's main intratumoral oncology therapy under clinical development.

Clinical development programs5 %

INVINCIBLE-3 and INVINCIBLE-4 are the core studies advancing the lead candidate.

Manufacturing and CMC activities5 %

GMP batch production, labeling, stability testing, and related supply work for trials.

Customers

The company does not yet sell products and has not generated revenue from product sales or licensing. Its near-term 'customers' are clinical trial sites, investigators, regulators, and eventually oncology patients and treating physicians if INT230-6 is approved. Any future commercial buyers would likely include hospitals, cancer centers, and payers supporting oncology treatment access.

Clinical trial sites and investigators

They administer the studies, collect data, and generate the evidence needed for regulatory approval.

Oncology patients

Patients with solid tumors are the intended end users of the intratumoral therapy in trials and, later, commercialization.

Regulators

FDA and other agencies determine whether the product can advance from trials to marketing approval.

Hospitals and cancer centers

These would be the main institutional buyers if the therapy reaches market and is adopted in oncology practice.

Strategy

Intensity Therapeutics is focused on funding and advancing its INVINCIBLE-3 and INVINCIBLE-4 studies, while building the manufacturing, regulatory, and organizational infrastructure needed for approval. The company also needs to preserve intellectual property and prepare a future commercial platform, but its strategy remains dependent on external financing until any product reaches market.

Advance clinical trialsShort term

Clinical proof-of-concept is the main value driver for a pre-revenue biotech company.

Secure manufacturing supplyShort term

GMP batches and stability testing are required to support ongoing trials and future approval.

Prepare for regulatory and commercial launchMedium term

Approval and eventual launch require regulatory filings, sales capability, and medical affairs readiness.

Geography

The company is based in the United States and its operations are centered on U.S.-based clinical development, manufacturing, and capital markets access. The filings do not disclose meaningful country revenue because the company has not generated product revenue. Geography matters mainly through U.S. regulatory oversight, domestic trial execution, and exposure to U.S. tariff and import/export policy for clinical supply chains.

Risks

The company is highly dependent on clinical success, regulatory approval, and the ability to raise capital before any product revenue exists. It also faces typical biotech risks such as trial delays, manufacturing complexity, IP protection, and commercialization uncertainty, plus the specific risk of Nasdaq listing compliance and policy changes affecting imports and tariffs.

Sorted by severity
LowMediumHighLowMediumHighImpact →Likelihood →Financing risk1Nasdaq delisting risk3Regulatory approval risk4
Impact is the risk’s severity and likelihood how probable it is over the next few years, both assessed from the company’s reports. Numbers match the list.
  1. Financing riskImpact: CriticalLikelihood: High

    The company expects to fund operations through equity, debt, or collaborations until commercialization.

    Exposure: Operating runway and trial funding

  2. Clinical development failureImpact: Critical

    INT230-6 must show safety and efficacy in trials before it can generate revenue.

    Exposure: INVINCIBLE-3 and INVINCIBLE-4

  3. Nasdaq delisting riskImpact: HighLikelihood: High

    Failure to regain compliance with listing standards could reduce liquidity and capital access.

    Exposure: Common stock trading and future fundraising

  4. Regulatory approval riskImpact: HighLikelihood: Low

    Even successful trials may not translate into marketing approval or commercial launch.

    Exposure: FDA and other health authorities

  5. Trade policy and tariff riskImpact: Medium

    Clinical and manufacturing inputs may be affected by import/export rules and tariffs.

    Exposure: Supply chain and third-party manufacturing

Accounting

Judgemental items
Research and development expense recognition

Clinical, manufacturing, and personnel costs are expensed immediately and dominate the income statement.

Impact: Directly affects operating loss and cash burn

Stock-based compensation

Employee options and consultant warrants create non-cash expense and dilution.

Impact: Affects reported operating expense and share count

Equity financing and warrant accounting

Recent offerings and warrants may require valuation judgments and influence dilution.

Impact: Affects equity balances and per-share metrics

Similar listed companies

Publicly listed companies with a comparable business focus.

Context Therapeutics Inc.

CNTX · Pharmaceutical Preparations

Inhibitor Therapeutics, Inc.

INTI · Pharmaceutical Preparations

Indaptus Therapeutics, Inc.

INDP · Pharmaceutical Preparations

Marker Therapeutics, Inc.

MRKR · Pharmaceutical Preparations

BriaCell Therapeutics Corp.

BCTXZ · Pharmaceutical Preparations

Actinium Pharmaceuticals, Inc.

ATNM · Pharmaceutical Preparations

Last updated: 24/09/2026